The Medpace Executive Management
August J. Troendle, MD
President and CEO
Dr.Troendle has been the President since having founded Medpace in 1992. His vision and strategic direction for Medpace has been a key factor in the growth of the company as a pre-eminent full-service CRO - serving sponsors in both drug and device
development in over 45 countries. He previously worked for Sandoz (Novartis) where he was responsible for the clinical development of lipid altering agents.
His past experience as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA gives him insight into the regulatory environment for development of drugs in the metabolic and cardiovascular fields.
Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine.
Jesse Geiger, CPA
COO, Laboratory Operations and CFO
Mr. Geiger provides leadership for Medpace’s laboratory operations, as well as for the early stage clinical pharmacology business and the global finance and information
technology organizations. He joined Medpace in 2007 as Corporate Controller where he continued on to lead the finance organization as CFO in 2011.
As CFO, he was instrumental in leading Medpace through two equity recapitalizations, most recently Cinven in early 2014, positioning Medpace as a preeminent global CRO.
His past experiences prior to Medpace include both public accounting and other senior corporate finance roles. Mr. Geiger received his BBA degree in Accounting
from the University of Cincinnati and is a Certified Public Accountant.